Ras基因激活与乳腺癌发生及临床预后的关系

Relationship between H-ras oncogenes activation and development and clinical prognosis of breast cancer

目的 探讨ras基因激活与乳腺癌发生及临床预后的关系。方法 采用LSAB免疫组化法对 8例乳腺纤维腺瘤、76例乳腺癌、3 4例淋巴结转移灶进行P2 1蛋白检测 ;用PCR -RFLP法对 6例乳腺纤维腺瘤、2 2例乳腺癌 ( 6例新鲜标本 )组织进行H ras12位点点突变检测。结果 76例乳腺癌P2 1蛋白表达率为 76.3 % ,伴淋巴结转移组阳性率明显高于无转移组 (P <0 .0 5 ) ;与组织学分级比较 ,Ⅰ级P2 1蛋白阳性率明显低于Ⅱ、Ⅲ级 (P <0 .0 5 ) ;随着临床分期的升高P2 1蛋白表达率有增高的趋势。H ras12位点点突变率在乳腺纤维腺瘤为 16.7%、乳腺癌为 2 7.3 % ,其中伴淋巴结转移组 3 7.5 %、无转移组 2 8.6%。结论 ras基因激活与乳腺癌的发生及转移有关。H ras12位点点突变率明显低于P2 1蛋白表达率 ,说明该位点突变并非是乳腺癌的主要激活方式。

? Objective H ras oncogenes point mutation at codon 12 and its protein expression were analysed to detect the relationship with the development and progress of braste cancer.Methods LSAB immunohistochemical technique was used to detect the expression of P21 protein in 76 cases of primary breast cancer,34 cases of lymphnode metastastic tissues,8 cases of breast fibroadenoma,meanwhile PCR RFLP method was used to analyse 22 cases of breast cancer and 6 cases of breast fibroadenoma.Results The positive rate of P21 protein was 76.3% in 76 cases of breast cancer,which was significantly higher in node positive group than in node negative one (P<0.05).The positive rate of P21 protein expression was significantly lower in grade Ⅰ than grade Ⅱ,Ⅲ and synchronously incresed with clinial stages.The frequency of H ras oncogenes point mutation at codon12 was 16.7% in fibroadenoma,27.3% in breast cancer,37.5% in node positive group and 28.6% in node negative one.Conclusions The ras oncogenes activation was related with the development and metastasis of breast cancer.H ras oncogenes point mutation rate at codon 12 was much lower than P21 protein expression rate,which showing point mutation at codon12 was not the major activating way of ras oncogenes in human breast cancer.〔